Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Comparative (5 Groups), Non-randomized, Multicenter, Physiopathological Study, Evaluating Pharmacokinetic Characteristics of Serum Hepcidin Level in Response to Iron Oral Intake in Order to Evaluate Their Interest to Discriminate Patients With Dysmetabolic Hepatosiderosis or Ferroportin Disease.

NCT01949467 is registered in ClinicalTrials.gov with Rennes University Hospital as lead sponsor.

NCT NCT01949467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01949467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Comparative (5 Groups), Non-randomized, Multicenter, Physiopathological Study, Evaluating Pharmacokinetic Characteristics of Serum Hepcidin Level in Response to Iron Oral Intake in Order to Evaluate Their Interest to Discriminate Patients With Dysmetabolic Hepatosiderosis or Ferroportin Disease.
Lead sponsor
Rennes University Hospital
Phase
Phase 2
Overall status
Completed
Start date
February 10, 2014
Completion date
December 26, 2018
Enrollment
62 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

diagnosis, dysmetabolic hepatosiderosis, ferroportin disease, hemochromatosis, type 4